Select your country
Websites worldwide
Select a country to go to the website of the respective STADA sales company.
Australia (1)
Austria (1)
Belarus (1)
Belgium (1)
Bosnia-Herzegovina (1)
Bulgaria (1)
China (1)
Croatia (1)
Czech Republic (2)
Denmark (1)
France (1)
Hungary (1)
Ireland (1)
Italy (1)
Montenegro (1)
Netherlands (2)
Poland (1)
Portugal (1)
Romania (1)
Saudi Arabia (1)
Serbia (1)
Slovakia (1)
Slovenia (1)
Spain (1)
Switzerland (1)
The Phillippines (1)
United Kingdom (3)
Vietnam (2)
STADA has recenty expanded its presence in nephrology beyond biosimilars to provide an innovative treatment for kidney health. Through a strategic partnership established in 2022, STADA secured the first European approval for a treatment for a rare kidney disease immunoglobulin A nephropathy (IgAN). This treatment benefits a small and under-served patient population and is classified as an “orphan drug” with a market exclusivity period of 10 years.
In line with STADA’s purpose of Caring for People’s Health as a Trusted Partner, the group continues to explore opportunities to develop and market further medicines in nephrology.
